Optimizing Two Antiplatelet Regimens Based on the CYP2C19 Gene Detection
10.3870/j.issn.1004-0781.2016.05.014
- VernacularTitle:基于 CYP2C19基因检测优化两种抗血小板治疗方案
- Author:
Jing WEI
;
Xiaoyan ZHAO
- Publication Type:Journal Article
- Keywords:
Ticagrelor;
Clopidogrel;
CYP2C19 gene;
Platelet aggregation
- From:
Herald of Medicine
2016;35(5):485-488
- CountryChina
- Language:Chinese
-
Abstract:
Objective To select antiplatelet regimen according to the results of CYP2C19 gene polymorphism,and then compare the major adverse cardiac events,bleeding events and the incidence of adverse reactions between two antiplatelet regimens. Methods Two hundred and seven patients who were diagnosed with acute coronary syndrome(ACS)and underwent elective PCI were tested for CYP2C19 genetic polymorphism,and 94 cases with CYP2C19 intermediate metabolism were randomly divided into high-dose clopidogrel group and ticagrelor group(47 cases each).High-dose clopidogrel group was given clopidogrel 150 mg once daily,and ticagrelor group ticagrelor 180 mg twice daily.Major adverse cardiac events,bleeding events and the incidence of adverse reactions were observed between two groups one month later. Results The average declined platelet aggregation rate was significantly different between the two groups[(6.27±5.65)% and(12.30±10.23)%,P<0.01];Adverse drug reactions ,the incidence of bleeding events and major adverse cardiac events of two groups were not significantly different. Conclusion Ticagrelor has stronger antiplatelet aggregation effects than high-dose clopidogrel.There is no difference in short-term clinical outcomes between the two groups.
